The Prognostic Value of Comorbidity for the Severity of COVID-19: A Systematic Review and Meta-analysis Study
Overview
Authors
Affiliations
Background And Objectives: With the increase in the number of COVID-19 infections, the global health apparatus is facing insufficient resources. The main objective of the current study is to provide additional data regarding the clinical characteristics of the patients diagnosed with COVID-19, and in particular to analyze the factors associated with disease severity, lack of improvement, and mortality.
Methods: 102 studies were included in the present meta-analysis, all of which were published before September 24, 2020. The studies were found by searching a number of databases, including Scopus, MEDLINE, Web of Science, and Embase. We performed a thorough search from early February until September 24. The selected papers were evaluated and analyzed using Stata software application version 14.
Results: Ultimately, 102 papers were selected for this meta- analysis, covering 121,437 infected patients. The mean age of the patients was 58.42 years. The results indicate a prevalence of 79.26% for fever (95% CI: 74.98-83.26; I2 = 97.35%), 60.70% for cough (95% CI: 56.91-64.43; I2 = 94.98%), 33.21% for fatigue or myalgia (95% CI: 28.86-37.70; I2 = 96.12%), 31.30% for dyspnea (95% CI: 26.14-36.69; I2 = 97.67%), and 10.65% for diarrhea (95% CI: 8.26-13.27; I2 = 94.20%). The prevalence for the most common comorbidities was 28.30% for hypertension (95% CI: 23.66-33.18; I2 = 99.58%), 14.29% for diabetes (95% CI: 11.88-16.87; I2 = 99.10%), 12.30% for cardiovascular diseases (95% CI: 9.59-15.27; I2 = 99.33%), and 5.19% for chronic kidney disease (95% CI: 3.95-6.58; I2 = 96.42%).
Conclusions: We evaluated the prevalence of some of the most important comorbidities in COVID-19 patients, indicating that some underlying disorders, including hypertension, diabetes, cardiovascular diseases, and chronic kidney disease, can be considered as risk factors for patients with COVID-19 infection. Furthermore, the results show that an elderly male with underlying diseases is more likely to have severe COVID-19.
Sumsuzzman D, Ye Y, Wang Z, Pandey A, Langley J, Galvani A BMC Infect Dis. 2025; 25(1):215.
PMID: 39948450 PMC: 11827239. DOI: 10.1186/s12879-025-10610-5.
Solanki G, Cleary S, Little F PLoS One. 2025; 20(1):e0317686.
PMID: 39854537 PMC: 11760578. DOI: 10.1371/journal.pone.0317686.
Eiken A, Bliddal S, Villumsen M, Iversen K, Bundgaard H, Hasselbach R PLoS One. 2024; 19(11):e0311260.
PMID: 39602471 PMC: 11602038. DOI: 10.1371/journal.pone.0311260.
Toll-like receptors polymorphisms and COVID-19: a systematic review.
Dos Santos B, Dos Santos L, Ferreira J, Dos Santos A, Sortica V, de Souza Figueiredo E Mol Cell Biochem. 2024; .
PMID: 39520513 DOI: 10.1007/s11010-024-05137-3.
Katic A, Rizvanovic N Med Int (Lond). 2024; 4(6):74.
PMID: 39483927 PMC: 11526207. DOI: 10.3892/mi.2024.198.